The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation

Medicine & Life Sciences

• gilteritinib 100%
• fms-Like Tyrosine Kinase 3 83%
• Acute Myeloid Leukemia 47%
• Mutation 28%
• European Union 17%
• Arm 13%
• Drug Therapy 11%
• Marketing 10%
• Survival 8%
• Therapeutics 8%
• Asthenia 6%
• Safety 5%
• Myalgia 5%
• Receptor Protein-Tyrosine Kinases 5%
• Arthralgia 5%
• Creatine Kinase 5%
• Dizziness 5%
• Constipation 5%
• Aspartate Aminotransferases 5%
• Alanine Transaminase 4%
• Cough 4%
• Hypotension 4%
• Tablets 4%
• Dyspnea 4%
• Alkaline Phosphatase 4%
• Nausea 4%
• Multicenter Studies 4%
• Fatigue 4%
• Diarrhea 4%
• Edema 4%
• Extremities 3%
• Cell Proliferation 3%
• Apoptosis 3%
• Confidence Intervals 2%
• Pain 2%